v3.26.1
Segment Reporting
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Segment Reporting
(14)
Segment Reporting
 
In accordance with FASB ASC Topic 280, Segment Reporting, the Company has determined that it operates as a single business segment, which is the development and commercialization of therapeutic and diagnostic products that service women’s reproductive health needs (fertility and permanent birth control).
 
The determination of a single business segment is consistent with the financial information regularly provided to the Company’s chief operating decision maker (“CODM”). As a single reportable segment entity, the Company’s segment performance measure is net loss attributable to shareholders. The measurement of segment assets is reported on the balance sheet as total assets. The Company’s CODM is its Chief Executive Officer and Chief Financial Officer, who together review and evaluate net income (loss) for purposes of assessing performance, making operating decisions, allocating resources, and planning and forecasting for future periods.
 
Significant segment expenses, as provided to the CODM, are as follows:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Three Months Ended June 30,
 
 
Six Months Ended June 30,
 
 
 
2026
 
 
2025
 
 
2026
 
 
2025
 
Sales
 
$
331,827
 
 
 
409,268
 
 
 
756,716
 
 
 
750,532
 
Cost of sales (excluding depreciation expense)
 
 
142,436
 
 
 
158,171
 
 
 
301,042
 
 
 
275,437
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Research and development expense
 
 
616,014
 
 
 
89,217
 
 
 
1,054,814
 
 
 
1,048,380
 
Other research and development expense1
 
 
1,330,864
 
 
 
1,325,212
 
 
 
2,201,465
 
 
 
3,334,521
 
Total research and development expense
 
 
1,946,878
 
 
 
1,414,429
 
 
 
3,256,279
 
 
 
4,382,901
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sales and marketing expense
 
 
1,293,998
 
 
 
984,977
 
 
 
2,609,753
 
 
 
1,893,544
 
General and administrative expense
 
 
1,931,578
 
 
 
1,616,972
 
 
 
3,713,968
 
 
 
3,339,685
 
Depreciation and amortization expense
 
 
82,811
 
 
 
86,285
 
 
 
165,081
 
 
 
171,138
 
Total operating expenses
 
 
5,255,265
 
 
 
4,102,663
 
 
 
9,745,081
 
 
 
9,787,268
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total other income (expense), net
 
 
597,644
 
 
 
(734,356
)
 
 
5,667,277
 
 
 
(1,174,776
)
Loss before income taxes
 
 
(4,468,230
)
 
 
(4,585,922
)
 
 
(3,622,130
)
 
 
(10,486,949
)
Income tax expense (benefit)
 
 
865
 
 
 
—
 
 
 
865
 
 
 
(4,188
)
Net loss
 
 
(4,469,095
)
 
 
(4,585,922
)
 
 
(3,622,995
)
 
 
(10,482,761
)
 
1 Other research and development expense include clinical affairs, regulatory, manufacturing and quality assurance expenses.